Navigation Links
Breckenridge Completes Acquisition of Certain Cypress Products from Pernix Therapeutics
Date:9/11/2013

BOCA RATON, Fla., Sept. 11, 2013 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has completed its acquisition of certain Cypress Pharmaceutical, Inc. product assets from Pernix Therapeutics. The assets include 11 Abbreviated New Drug Applications (ANDAs) filed with the FDA, certain ANDAs in various stages of development, as well as 6 already-approved and marketed products.  The company will begin distributing these Cypress-labeled products immediately, and the next phase will be converting these products to the Breckenridge label.  Customers have received detailed notices on the affected products and changes in ordering policies earlier today.

The assets include various unique dosage forms, such as ophthalmic, nasal spray, oral solution, syrup, and powder products, in addition to solid-oral products.  Breckenridge will begin marketing the approved products and continue to prosecute those ANDAs currently filed and pending with FDA.  "Breckenridge is excited to expand our current portfolio, as well as our R&D pipeline.  The Cypress assets are a natural fit to and complement the Breckenridge portfolio," stated Larry Lapila, Executive Vice President of Breckenridge Pharmaceutical, Inc. 

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories.  The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide.  The company markets over 70 products in a variety of dosage forms including:  Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and Powders.  www.bpirx.com


'/>"/>
SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Breckenridge Announces Approval for Pioglitazone Hydrochloride tablets
2. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
3. Breckenridge Pharmaceutical signs Letter of Intent with Welding GmbH & Co & SK Chemicals
4. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
5. Breckenridge Enters Into Agreement to Acquire Certain Cypress Assets from Pernix Therapeutics
6. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
9. CryoLife Completes Acquisition of Hemosphere
10. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
11. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
Breaking Medicine News(10 mins):